Literature DB >> 11576865

Rational drug discovery revisited: interfacing experimental programs with bio- and chemo-informatics.

J Bajorath1.   

Abstract

Over the past few years, bio- and chemo-informatics have rapidly evolved as related yet distinct disciplines. In drug discovery, it is increasingly recognized that combining and integrating these approaches is crucial for their successful application. In addition, the use of complementary experimental and informatics techniques increases the chances of success in many stages of the discovery process, from the identification of novel targets and elucidation of their functions to the discovery and development of lead compounds with desired properties. This review highlights recent trends that emphasize the role of integrated bio- and chemo-informatics research in drug discovery and discusses representative concepts and methodologies.

Year:  2001        PMID: 11576865     DOI: 10.1016/s1359-6446(01)01961-4

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  5 in total

1.  A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents.

Authors:  Haijun Chen; Cheng Z Wang; Chunyong Ding; Christopher Wild; Bryan Copits; Geoffrey T Swanson; Kenneth M Johnson; Jia Zhou
Journal:  ChemMedChem       Date:  2012-12-20       Impact factor: 3.466

2.  A need for a 'whole-istic functional genomics' approach in complex human diseases: arthritis.

Authors:  Ashok R Amin
Journal:  Arthritis Res Ther       Date:  2003-01-28       Impact factor: 5.156

3.  DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.

Authors:  Naiem T Issa; Jordan Kruger; Henri Wathieu; Rajarajan Raja; Stephen W Byers; Sivanesan Dakshanamurthy
Journal:  BMC Bioinformatics       Date:  2016-05-05       Impact factor: 3.169

4.  Identification of in vitro and in vivo disconnects using transcriptomic data.

Authors:  Martin Otava; Ziv Shkedy; Willem Talloen; Geert R Verheyen; Adetayo Kasim
Journal:  BMC Genomics       Date:  2015-08-18       Impact factor: 3.969

5.  Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.

Authors:  Ikechukwu Achilonu; Emmanuel Amarachi Iwuchukwu; Okechinyere Juliet Achilonu; Manuel Antonio Fernandes; Yasien Sayed
Journal:  J Mol Graph Model       Date:  2020-09-02       Impact factor: 2.518

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.